Evidence map›Paper›PMID 39189166›Full record

ArticlePathophysiology : the official journal of the International Society for Pathophysiology2024

STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes.

Kelli Morgan, James Morris, Qiang Cai, Phillip Kilgore, Urska Cvek, Marjan Trutschl, Katelynn T Lofton, Meher Sindhoora Mavuram, Prerana Ramesh, Nhi Dao and 2 more

Abstract read
In one paragraph

Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kelli MorganDepartment of Gastroenterology and Hepatology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
James MorrisDepartment of Gastroenterology and Hepatology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Qiang CaiDepartment of Gastroenterology and Hepatology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Phillip KilgoreDepartment of Computer Science, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Urska CvekDepartment of Computer Science, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-2042-6415
Marjan TrutschlDepartment of Computer Science, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Katelynn T LoftonDepartment of Molecular & Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Meher Sindhoora MavuramDepartment of Gastroenterology and Hepatology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Prerana RameshDepartment of Molecular & Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Nhi DaoDepartment of Molecular & Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Ahmed AlhaqueDepartment of Molecular & Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Jonathan Steven AlexanderDepartment of Molecular & Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0001-6975-3711

Funding

STABILITY' (symptomatic review during biologic therapy) Review in Inflammatory Bowel DiseaseP20GM103424 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI Seetharama D Jois · 2012 to 2026
$57.4M
NIGMS NIH HHS P20 GM103424NIH/NIGMS P2O GM103424.
6 · The paper itself

Abstract

Several studies have correlate improved patient outcomes with increased physician-patient contacts, particularly in chronic diseases. Extending this approach to inflammatory bowel disease (IBD) care presents a promising means of improving outcomes. At LSU Health Shreveport (LSUHS), a new approach called "STABILITY" (Symptomatic Review during Biologic Therapy) was implemented during infusion therapy visits for IBD patients. These brief 15 min physician-patient interviews aimed to discuss the patients' current IBD-related symptoms and evaluate the need for any changes in their treatment plan. Our goal was to remove a care gap and prevent intensifying symptoms created by missed appointments and loss of contact. To analyze the effectiveness of the STABILITY approach, a retrospective chart review was conducted on 111 IBD patients (18 with ulcerative colitis, 93 with Crohn's disease) seen at LSUHS between 2011 and 2022. Since March 2019, STABILITY has been mandatory for all infusion therapy visits. The data collected included patients' demographics, lab levels for biomarkers (fecal calprotectin, C-reactive protein, and erythrocyte sedimentation rates), hospitalizations, medication changes, and diagnosis dates before and after the implementation of STABILITY. Additionally, voluntary, anonymous infusion patient satisfaction surveys post-STABILITY were used to gather patient responses. In males with IBD, disease severity and hospitalizations were reduced significantly (

Indexed as

CDCrohn’s diseaseUCulcerative colitis

Identifiers

PMID39189166
PMCPMC11348379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.